COMP <GO>
AXSM vs KNSA // EV/EBITDA & P/E VALUATION
Axsome Therapeutics Inc. (NASDAQ) VS. Kiniksa Pharmaceuticals International plc (Class A) (NASDAQ) • 15-METRIC TALLY: AXSM 4
— KNSA 7
■ METRIC PARITY
LAST: $136.01 (-5.83%) • MKT CAP: $7.57B
valuation
—
LAST: $90.80 (-1.56%) • MKT CAP: $7.25B
valuation
95.0x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AXSM VS. KNSA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AXSM | KNSA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 88.50% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -21.90% | 9.90% | -31.80 | KNSA | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 95.0x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -1.25% | 1.78% | -3.03 | KNSA | /fcf-yield <GO> |
| Operating Margin | -26.10% | 11.40% | -37.50 | KNSA | /operating-margins <GO> |
| Net Profit Margin | -28.70% | 8.70% | -37.40 | KNSA | /net-margins <GO> |
| Revenue Growth (YoY) | 65.50% | 60.10% | +5.40 | AXSM | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.34 | 24.45 | -19.11 | KNSA | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 9/9 | -4.00 | KNSA | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 25.9 | 59.2 | -33.30 | KNSA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.15 | 1.11 | +0.04 | AXSM | /macro-sensitivity <GO> |
| Forward P/E Multiple | 35.0x | 109.1x | -74.10 | AXSM | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $7.57B | $7.25B | $317.9M | AXSM | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AXSM REV | KNSA REV | AXSM GROSS % | KNSA GROSS % | AXSM FCF | KNSA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $638.5M | $677.6M | — | 88.5% | -$93.9M | $136.4M |
| FY 2024 | $385.7M | $423.2M | — | 85.6% | -$128.7M | $25.4M |
| FY 2023 | $270.6M | $270.3M | — | — | -$157.3M | $1.1M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AXSM // BETA 1.15
KNSA // BETA 1.11